The UK's Defence Science and Technology Laboratory (DSTL) and Singapore’s MerLion Pharmaceuticals have secured a grant from the US Defense Threat Reduction Agency (DTRA) Chemical and Biological Defense Program to explore the use of finafloxacin against biological threat agents.

The post MerLion and UK’s DSTL to test finafloxacin against biological threat agents appeared first on Army Technology.